Bioventure and Al Razi Partners up With an Exclusive License Agreement for Oncology Product in KSA Market

Bioventure FZ LLC (“Bioventure”) and Al Razi Pharma Industries (“Al Razi”) sign an exclusive agreement for the commercialisation of an oncology product in the Kingdom of Saudi Arabia.

Bioventure, a subsidiary of Yas Holding’s healthcare division GlobalOne Healthcare Holding (GHH), and Al Razi Pharma Industries, a Saudi national pharmaceutical company which is a subsidiary of Saeed Raddad Group (SRG) in the Kingdom of Saudi Arabia, have entered into an exclusive license agreement for Pomalidomide.

This partnership grants Al Razi exclusive rights to register and hold marketing authorisation for Pomalidomide, a fully bioequivalent version of Imnovid. Pomalidomide is indicated in the treatment of adult patients with multiple myeloma.

“Alrazi Pharmaceutical Industries -as a major part of its Vision- is committed to securing high quality essential pharmaceutical medicinal products to the health care providers and the patients in Saudi Arabia. The Agreement with BioVenture is in alignment with the Kingdom of Saudi Arabia 2030 vision as it shall participate in localising the Marketing Authorization (MA) and commercialisation of one of the latest treatments of Multiple Myeloma.”, said Yasser Ebada, Alrazi’s General Manager.

“Bioventure is proud to partner with key players in the pharmaceutical and healthcare industries in the Middle East and UAE. Together, we are dedicated to making medicine more accessible to everyone who needs it.”- Ashraf Radwan, CEO of GlobalOne Healthcare Holding Commented.